Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications

Hepatitis B virus (HBV) core (HBc) virus-like particles (VLPs) are one of the most powerful protein engineering tools utilised to expose immunological epitopes and/or cell-targeting signals and for the packaging of genetic material and immune stimulatory sequences. Although HBc VLPs and their numero...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports Jg. 5; H. 1; S. 11639
Hauptverfasser: Strods, Arnis, Ose, Velta, Bogans, Janis, Cielens, Indulis, Kalnins, Gints, Radovica, Ilze, Kazaks, Andris, Pumpens, Paul, Renhofa, Regina
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 26.06.2015
Nature Publishing Group
Schlagworte:
101/28
631/337/475
639/638/92/612/1256
639/925/352/152
82/29
82/83
Alkalies - chemistry
Amino Acid Sequence
Core particles
Deoxyribonucleic acid
DNA
Electrophoresis, Polyacrylamide Gel
Epitopes
Gene therapy
Genetic Therapy - methods
Glutamic acid
Hepatitis
Hepatitis B
Hepatitis B Core Antigens - genetics
Hepatitis B Core Antigens - immunology
Hepatitis B Core Antigens - metabolism
Hepatitis B virus - genetics
Hepatitis B virus - immunology
Hepatitis B virus - metabolism
Humanities and Social Sciences
Hydrogen-Ion Concentration
Hydrolysis
Lysine
Microscopy, Electron
Molecular Sequence Data
multidisciplinary
Mutation
Nucleic acids
Nucleotide sequence
Packaging
Protein engineering
Ribonucleic acid
RNA
Science
Sequence Homology, Amino Acid
Spectrophotometry, Ultraviolet
Vaccines
Vaccines, Virus-Like Particle - immunology
Virion - genetics
Virion - immunology
Virion - metabolism
Virus Assembly - genetics
Virus Assembly - immunology
Virus-like particles
Yeast
ISSN:2045-2322, 2045-2322
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Hepatitis B virus (HBV) core (HBc) virus-like particles (VLPs) are one of the most powerful protein engineering tools utilised to expose immunological epitopes and/or cell-targeting signals and for the packaging of genetic material and immune stimulatory sequences. Although HBc VLPs and their numerous derivatives are produced in highly efficient bacterial and yeast expression systems, the existing purification and packaging protocols are not sufficiently optimised and standardised. Here, a simple alkaline treatment method was employed for the complete removal of internal RNA from bacteria- and yeast-produced HBc VLPs and for the conversion of these VLPs into empty particles, without any damage to the VLP structure. The empty HBc VLPs were able to effectively package the added DNA and RNA sequences. Furthermore, the alkaline hydrolysis technology appeared efficient for the purification and packaging of four different HBc variants carrying lysine residues on the HBc VLP spikes. Utilising the introduced lysine residues and the intrinsic aspartic and glutamic acid residues exposed on the tips of the HBc spikes for chemical coupling of the chosen peptide and/or nucleic acid sequences ensured a standard and easy protocol for the further development of versatile HBc VLP-based vaccine and gene therapy applications.
AbstractList Hepatitis B virus (HBV) core (HBc) virus-like particles (VLPs) are one of the most powerful protein engineering tools utilised to expose immunological epitopes and/or cell-targeting signals and for the packaging of genetic material and immune stimulatory sequences. Although HBc VLPs and their numerous derivatives are produced in highly efficient bacterial and yeast expression systems, the existing purification and packaging protocols are not sufficiently optimised and standardised. Here, a simple alkaline treatment method was employed for the complete removal of internal RNA from bacteria- and yeast-produced HBc VLPs and for the conversion of these VLPs into empty particles, without any damage to the VLP structure. The empty HBc VLPs were able to effectively package the added DNA and RNA sequences. Furthermore, the alkaline hydrolysis technology appeared efficient for the purification and packaging of four different HBc variants carrying lysine residues on the HBc VLP spikes. Utilising the introduced lysine residues and the intrinsic aspartic and glutamic acid residues exposed on the tips of the HBc spikes for chemical coupling of the chosen peptide and/or nucleic acid sequences ensured a standard and easy protocol for the further development of versatile HBc VLP-based vaccine and gene therapy applications.
Hepatitis B virus (HBV) core (HBc) virus-like particles (VLPs) are one of the most powerful protein engineering tools utilised to expose immunological epitopes and/or cell-targeting signals and for the packaging of genetic material and immune stimulatory sequences. Although HBc VLPs and their numerous derivatives are produced in highly efficient bacterial and yeast expression systems, the existing purification and packaging protocols are not sufficiently optimised and standardised. Here, a simple alkaline treatment method was employed for the complete removal of internal RNA from bacteria- and yeast-produced HBc VLPs and for the conversion of these VLPs into empty particles, without any damage to the VLP structure. The empty HBc VLPs were able to effectively package the added DNA and RNA sequences. Furthermore, the alkaline hydrolysis technology appeared efficient for the purification and packaging of four different HBc variants carrying lysine residues on the HBc VLP spikes. Utilising the introduced lysine residues and the intrinsic aspartic and glutamic acid residues exposed on the tips of the HBc spikes for chemical coupling of the chosen peptide and/or nucleic acid sequences ensured a standard and easy protocol for the further development of versatile HBc VLP-based vaccine and gene therapy applications.Hepatitis B virus (HBV) core (HBc) virus-like particles (VLPs) are one of the most powerful protein engineering tools utilised to expose immunological epitopes and/or cell-targeting signals and for the packaging of genetic material and immune stimulatory sequences. Although HBc VLPs and their numerous derivatives are produced in highly efficient bacterial and yeast expression systems, the existing purification and packaging protocols are not sufficiently optimised and standardised. Here, a simple alkaline treatment method was employed for the complete removal of internal RNA from bacteria- and yeast-produced HBc VLPs and for the conversion of these VLPs into empty particles, without any damage to the VLP structure. The empty HBc VLPs were able to effectively package the added DNA and RNA sequences. Furthermore, the alkaline hydrolysis technology appeared efficient for the purification and packaging of four different HBc variants carrying lysine residues on the HBc VLP spikes. Utilising the introduced lysine residues and the intrinsic aspartic and glutamic acid residues exposed on the tips of the HBc spikes for chemical coupling of the chosen peptide and/or nucleic acid sequences ensured a standard and easy protocol for the further development of versatile HBc VLP-based vaccine and gene therapy applications.
ArticleNumber 11639
Author Pumpens, Paul
Ose, Velta
Bogans, Janis
Strods, Arnis
Cielens, Indulis
Radovica, Ilze
Kalnins, Gints
Renhofa, Regina
Kazaks, Andris
Author_xml – sequence: 1
  givenname: Arnis
  surname: Strods
  fullname: Strods, Arnis
  organization: Latvian Biomedical Research and Study Centre
– sequence: 2
  givenname: Velta
  surname: Ose
  fullname: Ose, Velta
  organization: Latvian Biomedical Research and Study Centre
– sequence: 3
  givenname: Janis
  surname: Bogans
  fullname: Bogans, Janis
  organization: Latvian Biomedical Research and Study Centre
– sequence: 4
  givenname: Indulis
  surname: Cielens
  fullname: Cielens, Indulis
  organization: Latvian Biomedical Research and Study Centre
– sequence: 5
  givenname: Gints
  surname: Kalnins
  fullname: Kalnins, Gints
  organization: Latvian Biomedical Research and Study Centre
– sequence: 6
  givenname: Ilze
  surname: Radovica
  fullname: Radovica, Ilze
  organization: Latvian Biomedical Research and Study Centre
– sequence: 7
  givenname: Andris
  surname: Kazaks
  fullname: Kazaks, Andris
  organization: Latvian Biomedical Research and Study Centre
– sequence: 8
  givenname: Paul
  surname: Pumpens
  fullname: Pumpens, Paul
  organization: Latvian Biomedical Research and Study Centre
– sequence: 9
  givenname: Regina
  surname: Renhofa
  fullname: Renhofa, Regina
  organization: Latvian Biomedical Research and Study Centre
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26113394$$D View this record in MEDLINE/PubMed
BookMark eNptks2OFCEQgIlZ467rHnwBQ-JFTcZtoGGai4lu_Es20YOeCU0XM6w0tEBPMs_hC8vsrJNxlQskfPVVFcVjdBJiAISekuY1aVh3mRNMhAgmH6Az2rR8QRmlJ0fnU3SR801TF6eyJfIROqWCEMZke4Z-fa3hOuniYsD9Fmv_Q3sXAJcEuowQCtZhwAMU7TwM2KwrbAokl_cx0WIYp7LF6-oprriM3-GNS3PGJibAVV6c8ZCxjQlvtDE7-865gl2aNSQ91bzT5J25VeYn6KHVPsPF3X6Ovn94_-3q0-L6y8fPV2-vF6ZlXVkYWdthvWUN573tDBdssIYvTS-WxGopZW_6RpJOWrZkekmt7KhuJYBguuWGnaM3e-809yMMpjabtFdTcqNOWxW1U3_fBLdWq7hRreCN4LIKXtwJUvw5Qy5qdNmA9zpAnLMiQhIuO8lERZ_fQ2_inEJtT9UCZdtR2tFKPTuu6FDKn3lV4OUeMCnmOnl7QEijdt9BHb5DZS_vscaV2xeuzTj_34hX-4hcrWEF6ajIf-DfBdvJzA
CitedBy_id crossref_primary_10_1016_j_jobcr_2021_10_001
crossref_primary_10_3389_fbioe_2022_929243
crossref_primary_10_1016_j_ijbiomac_2024_130365
crossref_primary_10_1016_j_nano_2017_12_002
crossref_primary_10_1038_s41598_019_38533_7
crossref_primary_10_1002_elsc_202000104
crossref_primary_10_1038_srep37891
crossref_primary_10_1016_j_bbrc_2025_151704
crossref_primary_10_3390_biomedicines9111577
crossref_primary_10_1016_j_addr_2023_115134
crossref_primary_10_3390_microorganisms9020283
crossref_primary_10_1016_j_biochi_2018_11_001
crossref_primary_10_1016_j_copbio_2024_103070
crossref_primary_10_1002_bit_28063
crossref_primary_10_3389_fbioe_2024_1475918
crossref_primary_10_1134_S0026893316040099
crossref_primary_10_3390_ijms20194903
crossref_primary_10_3390_microorganisms11040972
crossref_primary_10_3389_fbioe_2023_1192050
crossref_primary_10_1080_1061186X_2023_2193358
crossref_primary_10_1088_2043_6254_aa5e1d
crossref_primary_10_1007_s10529_018_2516_5
crossref_primary_10_1016_j_pep_2020_105747
crossref_primary_10_1371_journal_ppat_1007488
crossref_primary_10_1002_btm2_10049
crossref_primary_10_1002_bit_27868
crossref_primary_10_3389_fbioe_2020_00881
crossref_primary_10_3390_v16010013
crossref_primary_10_1134_S0026893319030154
crossref_primary_10_1007_s12033_015_9895_9
crossref_primary_10_3389_fimmu_2020_00283
crossref_primary_10_1038_s41598_020_74105_w
crossref_primary_10_1080_14760584_2022_2029415
crossref_primary_10_1016_j_virol_2023_06_007
crossref_primary_10_3390_v14091905
Cites_doi 10.1371/journal.ppat.1000563
10.1073/pnas.1016404108
10.1128/JVI.01671-06
10.1073/pnas.94.26.14648
10.1016/j.canlet.2007.06.004
10.1016/j.bbrc.2004.12.118
10.1128/jvi.68.12.7993-8000.1994
10.1038/296677a0
10.1016/j.virol.2012.04.012
10.1073/pnas.94.18.9556
10.3390/v1020185
10.1128/JVI.74.24.11472-11478.2000
10.1074/jbc.M112.420521
10.1128/JVI.00586-10
10.1371/journal.pone.0075938
10.1016/0092-8674(94)90142-2
10.1128/jvi.68.9.5548-5555.1994
10.1201/9781420007305.ch9
10.1016/j.bpj.2011.10.002
10.1186/1471-2180-5-33
10.1128/jvi.65.11.6024-6030.1991
10.1128/JVI.75.14.6367-6374.2001
10.1371/journal.pone.0017202
10.1073/pnas.0504874102
10.1016/S1097-2765(01)80009-5
10.1128/jvi.63.11.4645-4652.1989
10.1128/jvi.66.9.5232-5241.1992
10.1111/j.1365-2249.2010.04226.x
10.1073/pnas.0502138102
10.1128/JVI.74.10.4721-4728.2000
10.1128/JVI.79.3.1871-1887.2005
10.1371/journal.pone.0102235
10.1038/330381a0
10.1016/0003-2697(73)90374-6
10.1002/jmv.20939
10.1016/S0378-4347(00)00538-7
10.1586/erv.09.121
10.1016/S0014-5793(00)01927-X
10.1016/j.vaccine.2013.07.052
10.1016/j.jmb.2012.06.032
10.1016/j.bbrc.2009.10.016
10.1128/jvi.59.1.176-180.1986
10.1006/viro.1999.9798
10.1016/j.pep.2010.09.010
10.1128/jvi.64.7.3319-3330.1990
10.1016/0378-1119(86)90177-0
10.1006/viro.1994.1413
10.1016/j.chembiol.2008.03.018
10.1002/biot.200800160
10.4049/jimmunol.172.3.1777
10.1016/j.nano.2012.05.003
10.1128/jvi.42.3.761-766.1982
10.1016/0014-5793(85)80771-7
10.1016/0161-5890(89)90130-2
10.1159/000346773
10.1128/JVI.02033-09
10.1021/mp200389t
10.1128/jvi.66.7.4107-4116.1992
10.1128/JVI.00749-09
10.1099/vir.0.80580-0
10.1073/pnas.89.21.10046
10.1586/eri.11.105
10.1038/srep00005
10.1159/000050037
10.1093/emboj/21.5.876
10.1073/pnas.1200808109
10.1128/JVI.75.14.6359-6366.2001
ContentType Journal Article
Copyright The Author(s) 2015
Copyright Nature Publishing Group Jun 2015
Copyright © 2015, Macmillan Publishers Limited 2015 Macmillan Publishers Limited
Copyright_xml – notice: The Author(s) 2015
– notice: Copyright Nature Publishing Group Jun 2015
– notice: Copyright © 2015, Macmillan Publishers Limited 2015 Macmillan Publishers Limited
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.1038/srep11639
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
ProQuest_Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef

MEDLINE - Academic
Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: PIMPY
  name: ProQuest Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
ExternalDocumentID PMC4650659
26113394
10_1038_srep11639
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
EJD
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFFHD
AFPKN
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c438t-c92943bf3055bf8c563dfc57cb671fa999bcb09189f373a72f982a49ee63a45c3
IEDL.DBID M7P
ISICitedReferencesCount 39
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000356932800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2045-2322
IngestDate Tue Nov 04 01:58:52 EST 2025
Sun Nov 09 14:15:05 EST 2025
Tue Oct 07 07:23:13 EDT 2025
Mon Jul 21 06:08:25 EDT 2025
Sat Nov 29 05:07:17 EST 2025
Tue Nov 18 21:28:36 EST 2025
Fri Feb 21 02:39:29 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c438t-c92943bf3055bf8c563dfc57cb671fa999bcb09189f373a72f982a49ee63a45c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/1899482282?pq-origsite=%requestingapplication%
PMID 26113394
PQID 1899482282
PQPubID 2041939
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4650659
proquest_miscellaneous_1691598936
proquest_journals_1899482282
pubmed_primary_26113394
crossref_primary_10_1038_srep11639
crossref_citationtrail_10_1038_srep11639
springer_journals_10_1038_srep11639
PublicationCentury 2000
PublicationDate 2015-06-26
PublicationDateYYYYMMDD 2015-06-26
PublicationDate_xml – month: 06
  year: 2015
  text: 2015-06-26
  day: 26
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2015
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References SeiferMStandringDNA protease-sensitive hinge linking the two domains of the hepatitis B virus core protein is exposed on the viral capsid surfaceJ Virol199468554855551:CAS:528:DyaK2cXlsFaqt70%3D7520091236955
Lloyd, D. D. Delloyd’s Lab Tech resources reagents and Solutions, <http://delloyd.50megs.com/moreinfo/buffers2.html>, (2014) (Date of access: 28/01/2015).
ChainBMMyersRVariability and conservation in hepatitis B virus core proteinBMC Microbiol20055331:CAS:528:DC%2BD2MXpslWgsrw%3D10.1186/1471-2180-5-33159215131173110
LeeKWTeyBTHoKLTejoBATanWSNanoglue: an alternative way to display cell-internalizing peptide at the spikes of hepatitis B virus core nanoparticles for cell-targeting deliveryMol Pharm20129241524231:CAS:528:DC%2BC38XpvVKlur8%3D10.1021/mp200389t22775561
LewellynEBLoebDDSerine phosphoacceptor sites within the core protein of hepatitis B virus contribute to genome replication pleiotropicallyPLoS One20116e172021:CAS:528:DC%2BC3MXislCnsLw%3D2011PLoSO...617202L10.1371/journal.pone.0017202213588053039676
FreivaldsJHighly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastorisProtein Expr Purif2011752182241:CAS:528:DC%2BC3cXhsVGntbzL10.1016/j.pep.2010.09.01020854910
JiangXStructures of arenaviral nucleoproteins with triphosphate dsRNA reveal a unique mechanism of immune suppressionJ Biol Chem201328816949169591:CAS:528:DC%2BC3sXptVCqtr0%3D10.1074/jbc.M112.420521236159023675627
BeteramsGBottcherBNassalMPackaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsidsFEBS Lett20004811691761:CAS:528:DC%2BD3cXmtlGqsLo%3D2000PhLB..481..199B10.1016/S0014-5793(00)01927-X
MengDHjelmRPHuJWuJA theoretical model for the dynamic structure of hepatitis B nucleocapsidBiophys J2011101247624841:CAS:528:DC%2BC3MXhsV2msb7O10.1016/j.bpj.2011.10.002220987463218330
PorterfieldJZFull-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativityJ Virol201084717471841:CAS:528:DC%2BC3cXhtVWls7nN10.1128/JVI.00586-10204275222898219
Renhofa, R. et al. inventors. Latvian Biomedical Research and Study Centre, assignee. Modificēti HBV core nanokonteineri kā universāla platforma bioloģiskā materiāla eksponēšanai. Latvia patent application. P-14-06. 13 Jan 2014.
HastieKMKimberlinCRZandonattiMAMacRaeIJSaphireEOStructure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3’ to 5’ exonuclease activity essential for immune suppressionProc Natl Acad Sci USA2011108239624012011PNAS..108.2396H10.1073/pnas.101640410821262835
Kann, M. & Gerlich, W. H. Replication of hepatitis B virus in Molecular Medicine of Viral Hepatitis (eds T. J. Harrison & A. J. Zuckerman ), 63–87 (John Wiley & Sons, 1997).
DhasonMSWangJCHaganMFZlotnickADifferential assembly of Hepatitis B Virus core protein on single- and double-stranded nucleic acid suggest the dsDNA-filled core is spring-loadedVirology201243020291:CAS:528:DC%2BC38XntFans70%3D10.1016/j.virol.2012.04.01222595445
WynneSACrowtherRALeslieAGThe crystal structure of the human hepatitis B virus capsidMol Cell199937717801:CAS:528:DyaK1MXktlOktbs%3D10.1016/S1097-2765(01)80009-5
BichkoVPushkoPDreilinaDPumpenPGrenESubtype ayw variant of hepatitis B virus. DNA primary structure analysisFEBS Lett19851852082121:CAS:528:DyaL2MXkvVamtrk%3D10.1016/0014-5793(85)80771-7
RabeBNuclear entry of hepatitis B virus capsids involves disintegration to protein dimers followed by nuclear reassociation to capsidsPLoS Pathog20095e10005631:CAS:528:DC%2BD1MXhtVOqsLjN10.1371/journal.ppat.1000563197142362727048
GuoYCrimean-Congo hemorrhagic fever virus nucleoprotein reveals endonuclease activity in bunyavirusesProc Natl Acad Sci USA2012109504650512012PNAS..109.5046G10.1073/pnas.120080810922421137
WalkerASkamelCNassalMSplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structureSci Rep2011151:CAS:528:DC%2BC3MXhtFyhtrfL2011NatSR...1E...5W10.1038/srep0000522355524
PackianathanCKatenSPDannCE3rdZlotnickAConformational changes in the hepatitis B virus core protein are consistent with a role for allostery in virus assemblyJ Virol201084160716151:CAS:528:DC%2BC3cXitFKjt7o%3D10.1128/JVI.02033-0919939922
VanlandschootPVan HoutteFSerruysBLeroux-RoelsGThe arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfateJ Gen Virol20058675841:CAS:528:DC%2BD2MXlt1KhtA%3D%3D10.1099/vir.0.80580-015604433
KannMGerlichWHEffect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virusJ Virol199468799380001:CAS:528:DyaK2MXitFylsrs%3D7966589237262
PushkoPPumpensPGrensEDevelopment of virus-like particle technology from small highly symmetric to large complex virus-like particle structuresIntervirology2013561411651:CAS:528:DC%2BC3sXotFWgsLc%3D10.1159/00034677323594863
KniskernPJUnusually high-level expression of a foreign gene (hepatitis B virus core antigen) in Saccharomyces cerevisiaeGene1986461351411:CAS:528:DyaL2sXksV2qsw%3D%3D10.1016/0378-1119(86)90177-0
BraunSProteasomal degradation of core protein variants from chronic hepatitis B patientsJ Med Virol200779131213211:CAS:528:DC%2BD2sXptFKiurg%3D10.1002/jmv.2093917607782
Renhofa, R., Dishlers, A., Ose-Klinklava, V., Ozols, J. & Pumpens, P., inventors. Latvian Biomedical Research and Study Centre, assignee. Packaging of magnetic nanoparticles into HBV core protein-formed capsids. Latvia patent. LV 14304 B. 20 May 2011.
NewmanMChuaPKTangFMSuPYShihCTesting an electrostatic interaction hypothesis of hepatitis B virus capsid stability by using an in vitro capsid disassembly/reassembly systemJ Virol20098310616106261:CAS:528:DC%2BD1MXhtlClsbfO10.1128/JVI.00749-09196568972753136
MachidaAPhosphorylation in the carboxyl-terminal domain of the capsid protein of hepatitis B virus: evaluation with a monoclonal antibodyJ Virol199165602460301:CAS:528:DyaK3MXmslGntLg%3D1717713250268
PerlmanDHBergEAO’ConnorPBCostelloCEHuJ Reverse transcription-associated dephosphorylation of hepadnavirus nucleocapsidsProc Natl Acad Sci USA2005102902090251:CAS:528:DC%2BD2MXmtVSjsrY%3D2005PNAS..102.9020P10.1073/pnas.050213810215951426
MosesSELimZZuckermanMAHepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipientsExpert Rev Anti Infect Ther2011989189910.1586/eri.11.10521973301
Pumpens, P. et al. Construction of novel vaccines on the basis of the virus-like particles: Hepatitis B virus proteins as vaccine carriers in Medicinal Protein Engineering (ed. Y. Khudyakov ), 205–248 (CRC Press, Taylor & Francis Group, 2008).
ZhouSStandringDNHepatitis B virus capsid particles are assembled from core-protein dimer precursorsProc Natl Acad Sci USA19928910046100501:CAS:528:DyaK3sXjsFGrsg%3D%3D1992PNAS...8910046Z10.1073/pnas.89.21.10046
PrasuhnDEJr.Polyvalent display of heme on hepatitis B virus capsid protein through coordination to hexahistidine tagsChem Biol2008155135191:CAS:528:DC%2BD1cXmtVSjsLk%3D10.1016/j.chembiol.2008.03.01818482703
StorniTNonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effectsJ Immunol2004172177717851:CAS:528:DC%2BD2cXptl2hsg%3D%3D10.4049/jimmunol.172.3.1777
MachidaAAntigenic sites on the arginine-rich carboxyl-terminal domain of the capsid protein of hepatitis B virus distinct from hepatitis B core or e antigenMol Immunol1989264134211:CAS:528:DyaL1MXktVGmsr4%3D10.1016/0161-5890(89)90130-2
SongSSignificant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumourClin Exp Immunol201016275831:CAS:528:DC%2BC3cXhtlSnsLfI10.1111/j.1365-2249.2010.04226.x207354402990932
BasagoudanavarSHPerlmanDHHuJRegulation of hepadnavirus reverse transcription by dynamic nucleocapsid phosphorylationJ Virol200781164116491:CAS:528:DC%2BD2sXhslKjs74%3D10.1128/JVI.01671-0617135319
HattonTZhouSStandringDNRNA- and DNA-binding activities in hepatitis B virus capsid protein: a model for their roles in viral replicationJ Virol199266523252411:CAS:528:DyaK38Xls1Ogtr8%3D1501273289076
ClarkeBEImproved immunogenicity of a peptide epitope after fusion to hepatitis B core proteinNature19873303813841:CAS:528:DyaL1cXjs1Shsw%3D%3D1987Natur.330..381C10.1038/330381a02446137
BorisovaGRecombinant capsid structures for exposure of protein antigenic epitopesMol Gen. (Life Sci Adv)19876169174
RosemanAMBerrimanJAWynneSAButlerPJCrowtherRAA structural model for maturation of the hepatitis B virus coreProc Natl Acad Sci USA200510215821158261:CAS:528:DC%2BD2MXht1Wru7nJ2005PNAS..10215821R10.1073/pnas.050487410216247012
KazaksABalmaksRVoronkovaTOseVPumpensPMelanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitopeBiotechnol J20083142914361:CAS:528:DC%2BD1cXhsV2qtrbE10.1002/biot.20080016018956370
Le PogamSChuaPKNewmanMShihCExposure of RNA templates and encapsidation of spliced viral RNA are influenced by the arginine-rich domain of human hepatitis B virus core antigen (HBcAg 165-173)J Virol200579187118871:CAS:528:DC%2BD2MXhtFCju7s%3D10.1128/JVI.79.3.1871-1887.200515650211544126
LangeMHepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodiesPLoS One20149e1022352014PLoSO...9j2235L10.1371/journal.pone.010223525014219
TumbanEPeabodyJPeabodyDSChackerianBA universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvantsVaccine201331464746541:CAS:528:DC%2BC3sXht12is77J10.1016/j.vaccine.2013.07.052239333373785330
BorisovaGPGenetically engineered mutants of the core antigen of the human hepatitis B virus preserving the ability for native self-assemblyDokl Akad Nauk SSSR1988298147414781:CAS:528:DyaL1cXkt1Sisrg
C Packianathan (BFsrep11639_CR5) 2010; 84
D Rolland (BFsrep11639_CR12) 2001; 753
EV Gazina (BFsrep11639_CR55) 2000; 74
A Walker (BFsrep11639_CR51) 2011; 1
R Ranka (BFsrep11639_CR50) 2013; 9
A Zlotnick (BFsrep11639_CR59) 1997; 94
T Cao (BFsrep11639_CR72) 2001; 75
AM Roseman (BFsrep11639_CR8) 2012; 423
JZ Porterfield (BFsrep11639_CR35) 2010; 84
MS Dhason (BFsrep11639_CR29) 2012; 430
S Zhou (BFsrep11639_CR3) 1992; 89
A Miyanohara (BFsrep11639_CR11) 1986; 59
S Song (BFsrep11639_CR64) 2010; 162
S Song (BFsrep11639_CR63) 2007; 256
A Machida (BFsrep11639_CR23) 1989; 26
RA Crowther (BFsrep11639_CR7) 1994; 77
M Nassal (BFsrep11639_CR21) 1992; 66
D Meng (BFsrep11639_CR26) 2011; 101
S Braun (BFsrep11639_CR65) 2007; 79
BFsrep11639_CR18
AM Roseman (BFsrep11639_CR58) 2005; 102
T Hatton (BFsrep11639_CR22) 1992; 66
KM Hastie (BFsrep11639_CR67) 2011; 108
BFsrep11639_CR74
GP Borisova (BFsrep11639_CR27) 1988; 298
S Schadler (BFsrep11639_CR47) 2009; 1
J Freivalds (BFsrep11639_CR13) 2011; 75
DR Milich (BFsrep11639_CR70) 1997; 94
DH Perlman (BFsrep11639_CR44) 2005; 102
SH Basagoudanavar (BFsrep11639_CR56) 2007; 81
B Ehresmann (BFsrep11639_CR73) 1973; 54
BFsrep11639_CR1
U Lazdina (BFsrep11639_CR71) 2001; 75
X Jiang (BFsrep11639_CR68) 2013; 288
M Seifer (BFsrep11639_CR15) 1994; 68
I Sominskaya (BFsrep11639_CR60) 2013; 8
A Machida (BFsrep11639_CR41) 1991; 65
B Rabe (BFsrep11639_CR40) 2009; 5
BM Chain (BFsrep11639_CR17) 2005; 5
MA Bundule (BFsrep11639_CR24) 1990; 312
G Beterams (BFsrep11639_CR62) 2000; 481
E Tumban (BFsrep11639_CR66) 2013; 31
SA Wynne (BFsrep11639_CR9) 1999; 3
F Birnbaum (BFsrep11639_CR14) 1990; 64
M Kann (BFsrep11639_CR61) 1994; 68
T Storni (BFsrep11639_CR31) 2004; 172
A Shlomai (BFsrep11639_CR30) 2009; 390
SE Moses (BFsrep11639_CR46) 2011; 9
KW Lee (BFsrep11639_CR53) 2012; 9
BE Clarke (BFsrep11639_CR48) 1987; 330
P Pumpens (BFsrep11639_CR6) 2001; 44
BFsrep11639_CR37
EB Lewellyn (BFsrep11639_CR45) 2011; 6
BFsrep11639_CR38
V Bichko (BFsrep11639_CR75) 1985; 185
P Pushko (BFsrep11639_CR39) 1994; 202
YT Lan (BFsrep11639_CR42) 1999; 259
BFsrep11639_CR36
NR Watts (BFsrep11639_CR16) 2002; 21
H Mabit (BFsrep11639_CR57) 2000; 74
BJ Cohen (BFsrep11639_CR4) 1982; 296
A Kazaks (BFsrep11639_CR32) 2008; 3
A Cooper (BFsrep11639_CR33) 2005; 327
P Pushko (BFsrep11639_CR20) 2013; 56
P Vanlandschoot (BFsrep11639_CR25) 2005; 86
Y Guo (BFsrep11639_CR69) 2012; 109
M Newman (BFsrep11639_CR34) 2009; 83
G Borisova (BFsrep11639_CR49) 1987; 6
WH Gerlich (BFsrep11639_CR2) 1982; 42
PJ Kniskern (BFsrep11639_CR10) 1986; 46
DC Whitacre (BFsrep11639_CR19) 2009; 8
M Lange (BFsrep11639_CR52) 2014; 9
DE Prasuhn Jr. (BFsrep11639_CR54) 2008; 15
A Gallina (BFsrep11639_CR28) 1989; 63
S Le Pogam (BFsrep11639_CR43) 2005; 79
2191149 - J Virol. 1990 Jul;64(7):3319-30
2446137 - Nature. 1987 Nov 26-Dec 2;330(6146):381-4
6808156 - J Virol. 1982 Jun;42(3):761-6
21262835 - Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2396-401
14734761 - J Immunol. 2004 Feb 1;172(3):1777-85
10394365 - Mol Cell. 1999 Jun;3(6):771-80
11509871 - Intervirology. 2001;44(2-3):98-114
23594863 - Intervirology. 2013;56(3):141-65
7966589 - J Virol. 1994 Dec;68(12):7993-8000
8004680 - Cell. 1994 Jun 17;77(6):943-50
19818740 - Biochem Biophys Res Commun. 2009 Dec 18;390(3):619-23
3520012 - J Virol. 1986 Jul;59(1):176-80
2677399 - J Virol. 1989 Nov;63(11):4645-52
23933337 - Vaccine. 2013 Sep 23;31(41):4647-54
22098746 - Biophys J. 2011 Nov 16;101(10):2476-84
7040981 - Nature. 1982 Apr 15;296(5858):677-9
9405667 - Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14648-53
22633898 - Nanomedicine. 2013 Jan;9(1):65-73
8030252 - Virology. 1994 Aug 1;202(2):912-20
19714236 - PLoS Pathog. 2009 Aug;5(8):e1000563
1501273 - J Virol. 1992 Sep;66(9):5232-41
23615902 - J Biol Chem. 2013 Jun 7;288(23):16949-59
22421137 - Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5046-51
10996318 - FEBS Lett. 2000 Sep 15;481(2):169-76
15951426 - Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):9020-5
17656012 - Cancer Lett. 2007 Oct 18;256(1):90-100
21358805 - PLoS One. 2011;6(2):e17202
11413302 - J Virol. 2001 Jul;75(14):6359-66
20854910 - Protein Expr Purif. 2011 Feb;75(2):218-24
7520091 - J Virol. 1994 Sep;68(9):5548-55
19656897 - J Virol. 2009 Oct;83(20):10616-26
11413303 - J Virol. 2001 Jul;75(14):6367-74
22750730 - J Mol Biol. 2012 Oct 12;423(1):63-78
15604433 - J Gen Virol. 2005 Jan;86(Pt 1):75-84
11867516 - EMBO J. 2002 Mar 1;21(5):876-84
21973301 - Expert Rev Anti Infect Ther. 2011 Oct;9(10):891-9
15650211 - J Virol. 2005 Feb;79(3):1871-87
15921513 - BMC Microbiol. 2005;5:33
1602535 - J Virol. 1992 Jul;66(7):4107-16
2226141 - Dokl Akad Nauk SSSR. 1990;312(4):993-6
17607782 - J Med Virol. 2007 Sep;79(9):1312-21
3542716 - Gene. 1986;46(1):135-41
25014219 - PLoS One. 2014;9(7):e102235
2837379 - Dokl Akad Nauk SSSR. 1988;298(6):1474-8
19863249 - Expert Rev Vaccines. 2009 Nov;8(11):1565-73
10388659 - Virology. 1999 Jul 5;259(2):342-8
18482703 - Chem Biol. 2008 May;15(5):513-9
10775610 - J Virol. 2000 May;74(10):4721-8
22595445 - Virology. 2012 Aug 15;430(1):20-9
16247012 - Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15821-6
15652509 - Biochem Biophys Res Commun. 2005 Feb 25;327(4):1094-9
20735440 - Clin Exp Immunol. 2010 Oct;162(1):75-83
17135319 - J Virol. 2007 Feb;81(4):1641-9
11302448 - J Chromatogr B Biomed Sci Appl. 2001 Mar 25;753(1):51-65
4737496 - Anal Biochem. 1973 Aug;54(2):454-63
3996597 - FEBS Lett. 1985 Jun 3;185(1):208-12
1438193 - Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10046-50
24086668 - PLoS One. 2013;8(9):e75938
9275161 - Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9556-61
22355524 - Sci Rep. 2011;1:5
18956370 - Biotechnol J. 2008 Nov;3(11):1429-36
1717713 - J Virol. 1991 Nov;65(11):6024-30
22775561 - Mol Pharm. 2012 Sep 4;9(9):2415-23
19939922 - J Virol. 2010 Feb;84(3):1607-15
2469950 - Mol Immunol. 1989 Apr;26(4):413-21
11090143 - J Virol. 2000 Dec;74(24):11472-8
20427522 - J Virol. 2010 Jul;84(14):7174-84
21994545 - Viruses. 2009 Sep;1(2):185-209
References_xml – reference: GuoYCrimean-Congo hemorrhagic fever virus nucleoprotein reveals endonuclease activity in bunyavirusesProc Natl Acad Sci USA2012109504650512012PNAS..109.5046G10.1073/pnas.120080810922421137
– reference: MiyanoharaAExpression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codonsJ Virol1986591761801:CAS:528:DyaL28XktlKrs7k%3D3520012
– reference: WhitacreDCLeeBOMilichDRUse of hepadnavirus core proteins as vaccine platformsExpert Rev Vaccines20098156515731:CAS:528:DC%2BD1MXhtleisbvL10.1586/erv.09.121198632492836209
– reference: WynneSACrowtherRALeslieAGThe crystal structure of the human hepatitis B virus capsidMol Cell199937717801:CAS:528:DyaK1MXktlOktbs%3D10.1016/S1097-2765(01)80009-5
– reference: RankaRFibronectin-binding nanoparticles for intracellular targeting addressed by B. burgdorferi BBK32 protein fragmentsNanomedicine2013965731:CAS:528:DC%2BC38XoslGls74%3D10.1016/j.nano.2012.05.00322633898
– reference: WattsNRThe morphogenic linker peptide of HBV capsid protein forms a mobile array on the interior surfaceEMBO J2002218768841:CAS:528:DC%2BD38XitFylsL0%3D10.1093/emboj/21.5.87611867516125892
– reference: GallinaAA recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acidsJ Virol198963464546521:CAS:528:DyaL1MXmtFejsr8%3D2677399251098
– reference: ClarkeBEImproved immunogenicity of a peptide epitope after fusion to hepatitis B core proteinNature19873303813841:CAS:528:DyaL1cXjs1Shsw%3D%3D1987Natur.330..381C10.1038/330381a02446137
– reference: Renhofa, R. et al. inventors. Latvian Biomedical Research and Study Centre, assignee. Paņēmiens izvēlēta materiāla piešūšanai HBV core proteīna veidotajām nanodaļiņām. Latvia patent application. P-14-05. 13 Jan 2014.
– reference: PushkoPIdentification of hepatitis B virus core protein regions exposed or internalized at the surface of HBcAg particles by scanning with monoclonal antibodiesVirology19942029129201:CAS:528:DyaK2cXltlWrtbg%3D10.1006/viro.1994.14138030252
– reference: RollandDPurification of recombinant HBc antigen expressed in Escherichia coli and Pichia pastoris: comparison of size-exclusion chromatography and ultracentrifugationJ Chromatogr B Biomed Sci Appl200175351651:CAS:528:DC%2BD3MXhvVWrurc%3D10.1016/S0378-4347(00)00538-7
– reference: SominskayaIA VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of micePLoS One20138e759381:CAS:528:DC%2BC3sXhsFKitrzK2013PLoSO...875938S10.1371/journal.pone.0075938240866683781094
– reference: SongSSignificant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumourClin Exp Immunol201016275831:CAS:528:DC%2BC3cXhtlSnsLfI10.1111/j.1365-2249.2010.04226.x207354402990932
– reference: LewellynEBLoebDDSerine phosphoacceptor sites within the core protein of hepatitis B virus contribute to genome replication pleiotropicallyPLoS One20116e172021:CAS:528:DC%2BC3MXislCnsLw%3D2011PLoSO...617202L10.1371/journal.pone.0017202213588053039676
– reference: ZhouSStandringDNHepatitis B virus capsid particles are assembled from core-protein dimer precursorsProc Natl Acad Sci USA19928910046100501:CAS:528:DyaK3sXjsFGrsg%3D%3D1992PNAS...8910046Z10.1073/pnas.89.21.10046
– reference: WalkerASkamelCNassalMSplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structureSci Rep2011151:CAS:528:DC%2BC3MXhtFyhtrfL2011NatSR...1E...5W10.1038/srep0000522355524
– reference: RosemanAMBerrimanJAWynneSAButlerPJCrowtherRAA structural model for maturation of the hepatitis B virus coreProc Natl Acad Sci USA200510215821158261:CAS:528:DC%2BD2MXht1Wru7nJ2005PNAS..10215821R10.1073/pnas.050487410216247012
– reference: CrowtherRAThree-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopyCell1994779439501:CAS:528:DyaK2cXkslyit7c%3D10.1016/0092-8674(94)90142-2
– reference: ChainBMMyersRVariability and conservation in hepatitis B virus core proteinBMC Microbiol20055331:CAS:528:DC%2BD2MXpslWgsrw%3D10.1186/1471-2180-5-33159215131173110
– reference: PorterfieldJZFull-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativityJ Virol201084717471841:CAS:528:DC%2BC3cXhtVWls7nN10.1128/JVI.00586-10204275222898219
– reference: BunduleMA[C-terminal polyarginine tract of hepatitis B core antigen is located on the outer capsid surface]Dokl Akad Nauk SSSR19903129939961:CAS:528:DyaK3cXls12qtbc%3D2226141
– reference: Renhofa, R. et al. inventors. Latvian Biomedical Research and Study Centre, assignee. Modificēti HBV core nanokonteineri kā universāla platforma bioloģiskā materiāla eksponēšanai. Latvia patent application. P-14-06. 13 Jan 2014.
– reference: KannMGerlichWHEffect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virusJ Virol199468799380001:CAS:528:DyaK2MXitFylsrs%3D7966589237262
– reference: BraunSProteasomal degradation of core protein variants from chronic hepatitis B patientsJ Med Virol200779131213211:CAS:528:DC%2BD2sXptFKiurg%3D10.1002/jmv.2093917607782
– reference: RabeBNuclear entry of hepatitis B virus capsids involves disintegration to protein dimers followed by nuclear reassociation to capsidsPLoS Pathog20095e10005631:CAS:528:DC%2BD1MXhtVOqsLjN10.1371/journal.ppat.1000563197142362727048
– reference: DhasonMSWangJCHaganMFZlotnickADifferential assembly of Hepatitis B Virus core protein on single- and double-stranded nucleic acid suggest the dsDNA-filled core is spring-loadedVirology201243020291:CAS:528:DC%2BC38XntFans70%3D10.1016/j.virol.2012.04.01222595445
– reference: ZlotnickALocalization of the C terminus of the assembly domain of hepatitis B virus capsid protein: implications for morphogenesis and organization of encapsidated RNAProc Natl Acad Sci USA199794955695611:CAS:528:DyaK2sXlvVSrtb0%3D1997PNAS...94.9556Z10.1073/pnas.94.18.9556
– reference: GazinaEVFieldingJELinBAndersonDACore protein phosphorylation modulates pregenomic RNA encapsidation to different extents in human and duck hepatitis B virusesJ Virol200074472147281:CAS:528:DC%2BD3cXivFynsr8%3D10.1128/JVI.74.10.4721-4728.2000
– reference: SongSAugmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpGCancer Lett2007256901001:CAS:528:DC%2BD2sXpvFGrtbc%3D10.1016/j.canlet.2007.06.00417656012
– reference: PerlmanDHBergEAO’ConnorPBCostelloCEHuJ Reverse transcription-associated dephosphorylation of hepadnavirus nucleocapsidsProc Natl Acad Sci USA2005102902090251:CAS:528:DC%2BD2MXmtVSjsrY%3D2005PNAS..102.9020P10.1073/pnas.050213810215951426
– reference: Pumpens, P. et al. Construction of novel vaccines on the basis of the virus-like particles: Hepatitis B virus proteins as vaccine carriers in Medicinal Protein Engineering (ed. Y. Khudyakov ), 205–248 (CRC Press, Taylor & Francis Group, 2008).
– reference: LeeKWTeyBTHoKLTejoBATanWSNanoglue: an alternative way to display cell-internalizing peptide at the spikes of hepatitis B virus core nanoparticles for cell-targeting deliveryMol Pharm20129241524231:CAS:528:DC%2BC38XpvVKlur8%3D10.1021/mp200389t22775561
– reference: PackianathanCKatenSPDannCE3rdZlotnickAConformational changes in the hepatitis B virus core protein are consistent with a role for allostery in virus assemblyJ Virol201084160716151:CAS:528:DC%2BC3cXitFKjt7o%3D10.1128/JVI.02033-0919939922
– reference: MabitHSchallerHIntracellular hepadnavirus nucleocapsids are selected for secretion by envelope protein-independent membrane bindingJ Virol20007411472114781:CAS:528:DC%2BD3MXitVGjtbc%3D10.1128/JVI.74.24.11472-11478.2000
– reference: MachidaAAntigenic sites on the arginine-rich carboxyl-terminal domain of the capsid protein of hepatitis B virus distinct from hepatitis B core or e antigenMol Immunol1989264134211:CAS:528:DyaL1MXktVGmsr4%3D10.1016/0161-5890(89)90130-2
– reference: MengDHjelmRPHuJWuJA theoretical model for the dynamic structure of hepatitis B nucleocapsidBiophys J2011101247624841:CAS:528:DC%2BC3MXhsV2msb7O10.1016/j.bpj.2011.10.002220987463218330
– reference: JiangXStructures of arenaviral nucleoproteins with triphosphate dsRNA reveal a unique mechanism of immune suppressionJ Biol Chem201328816949169591:CAS:528:DC%2BC3sXptVCqtr0%3D10.1074/jbc.M112.420521236159023675627
– reference: Kann, M. & Gerlich, W. H. Replication of hepatitis B virus in Molecular Medicine of Viral Hepatitis (eds T. J. Harrison & A. J. Zuckerman ), 63–87 (John Wiley & Sons, 1997).
– reference: StorniTNonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effectsJ Immunol2004172177717851:CAS:528:DC%2BD2cXptl2hsg%3D%3D10.4049/jimmunol.172.3.1777
– reference: EhresmannBImbaultPWeilJHSpectrophotometric determination of protein concentration in cell extracts containing tRNA’s and rRNA’sAnal Biochem1973544544631:CAS:528:DyaE3sXks1egsbY%3D10.1016/0003-2697(73)90374-6
– reference: Lloyd, D. D. Delloyd’s Lab Tech resources reagents and Solutions, <http://delloyd.50megs.com/moreinfo/buffers2.html>, (2014) (Date of access: 28/01/2015).
– reference: PumpensPGrensEHBV core particles as a carrier for B cell/T cell epitopesIntervirology200144981141:CAS:528:DC%2BD3MXmslyitb8%3D10.1159/000050037
– reference: BichkoVPushkoPDreilinaDPumpenPGrenESubtype ayw variant of hepatitis B virus. DNA primary structure analysisFEBS Lett19851852082121:CAS:528:DyaL2MXkvVamtrk%3D10.1016/0014-5793(85)80771-7
– reference: VanlandschootPVan HoutteFSerruysBLeroux-RoelsGThe arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfateJ Gen Virol20058675841:CAS:528:DC%2BD2MXlt1KhtA%3D%3D10.1099/vir.0.80580-015604433
– reference: MachidaAPhosphorylation in the carboxyl-terminal domain of the capsid protein of hepatitis B virus: evaluation with a monoclonal antibodyJ Virol199165602460301:CAS:528:DyaK3MXmslGntLg%3D1717713250268
– reference: MilichDRRole of B cells in antigen presentation of the hepatitis B coreProc Natl Acad Sci USA19979414648146531:CAS:528:DyaK1cXis1KhtQ%3D%3D1997PNAS...9414648M10.1073/pnas.94.26.14648
– reference: CohenBJRichmondJEElectron microscopy of hepatitis B core antigen synthesized in E. coliNature19822966776791:CAS:528:DyaL38XksFeltbY%3D1982Natur.296..677C10.1038/296677a0
– reference: LazdinaUMolecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cellsJ Virol200175636763741:CAS:528:DC%2BD3MXkvFSitr4%3D10.1128/JVI.75.14.6367-6374.200111413303114359
– reference: RosemanAMStructures of hepatitis B virus cores presenting a model epitope and their complexes with antibodiesJ Mol Biol201242363781:CAS:528:DC%2BC38XhtF2ntrjE10.1016/j.jmb.2012.06.032227507303465560
– reference: FreivaldsJHighly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastorisProtein Expr Purif2011752182241:CAS:528:DC%2BC3cXhsVGntbzL10.1016/j.pep.2010.09.01020854910
– reference: PrasuhnDEJr.Polyvalent display of heme on hepatitis B virus capsid protein through coordination to hexahistidine tagsChem Biol2008155135191:CAS:528:DC%2BD1cXmtVSjsLk%3D10.1016/j.chembiol.2008.03.01818482703
– reference: CaoTHepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse modelJ Virol200175635963661:CAS:528:DC%2BD3MXkvFSisbc%3D10.1128/JVI.75.14.6359-6366.200111413302114358
– reference: Renhofa, R., Dishlers, A., Ose-Klinklava, V., Ozols, J. & Pumpens, P., inventors. Latvian Biomedical Research and Study Centre, assignee. Packaging of magnetic nanoparticles into HBV core protein-formed capsids. Latvia patent. LV 14304 B. 20 May 2011.
– reference: TumbanEPeabodyJPeabodyDSChackerianBA universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvantsVaccine201331464746541:CAS:528:DC%2BC3sXht12is77J10.1016/j.vaccine.2013.07.052239333373785330
– reference: MosesSELimZZuckermanMAHepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipientsExpert Rev Anti Infect Ther2011989189910.1586/eri.11.10521973301
– reference: KniskernPJUnusually high-level expression of a foreign gene (hepatitis B virus core antigen) in Saccharomyces cerevisiaeGene1986461351411:CAS:528:DyaL2sXksV2qsw%3D%3D10.1016/0378-1119(86)90177-0
– reference: BeteramsGBottcherBNassalMPackaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsidsFEBS Lett20004811691761:CAS:528:DC%2BD3cXmtlGqsLo%3D2000PhLB..481..199B10.1016/S0014-5793(00)01927-X
– reference: SeiferMStandringDNA protease-sensitive hinge linking the two domains of the hepatitis B virus core protein is exposed on the viral capsid surfaceJ Virol199468554855551:CAS:528:DyaK2cXlsFaqt70%3D7520091236955
– reference: NassalMThe arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assemblyJ Virol199266410741161:CAS:528:DyaK38Xks1KgsLo%3D1602535241213
– reference: PushkoPPumpensPGrensEDevelopment of virus-like particle technology from small highly symmetric to large complex virus-like particle structuresIntervirology2013561411651:CAS:528:DC%2BC3sXotFWgsLc%3D10.1159/00034677323594863
– reference: CooperAShaulYRecombinant viral capsids as an efficient vehicle of oligonucleotide delivery into cellsBiochem Biophys Res Commun2005327109410991:CAS:528:DC%2BD2MXksFGmsw%3D%3D10.1016/j.bbrc.2004.12.11815652509
– reference: Le PogamSChuaPKNewmanMShihCExposure of RNA templates and encapsidation of spliced viral RNA are influenced by the arginine-rich domain of human hepatitis B virus core antigen (HBcAg 165-173)J Virol200579187118871:CAS:528:DC%2BD2MXhtFCju7s%3D10.1128/JVI.79.3.1871-1887.200515650211544126
– reference: HastieKMKimberlinCRZandonattiMAMacRaeIJSaphireEOStructure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3’ to 5’ exonuclease activity essential for immune suppressionProc Natl Acad Sci USA2011108239624012011PNAS..108.2396H10.1073/pnas.101640410821262835
– reference: GerlichWHGoldmannUMullerRStibbeWWolffWSpecificity and localization of the hepatitis B virus-associated protein kinaseJ Virol1982427617661:CAS:528:DyaL38XktF2ks7Y%3D6808156256908
– reference: LanYTLiJLiaoWOuJRoles of the three major phosphorylation sites of hepatitis B virus core protein in viral replicationVirology19992593423481:CAS:528:DyaK1MXktV2rtrs%3D10.1006/viro.1999.979810388659
– reference: LangeMHepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodiesPLoS One20149e1022352014PLoSO...9j2235L10.1371/journal.pone.010223525014219
– reference: NewmanMChuaPKTangFMSuPYShihCTesting an electrostatic interaction hypothesis of hepatitis B virus capsid stability by using an in vitro capsid disassembly/reassembly systemJ Virol20098310616106261:CAS:528:DC%2BD1MXhtlClsbfO10.1128/JVI.00749-09196568972753136
– reference: BasagoudanavarSHPerlmanDHHuJRegulation of hepadnavirus reverse transcription by dynamic nucleocapsid phosphorylationJ Virol200781164116491:CAS:528:DC%2BD2sXhslKjs74%3D10.1128/JVI.01671-0617135319
– reference: SchadlerSHildtEHBV life cycle: entry and morphogenesisViruses200911852091:CAS:528:DC%2BD1MXhsVagtLrM10.3390/v1020185219945453185491
– reference: KazaksABalmaksRVoronkovaTOseVPumpensPMelanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitopeBiotechnol J20083142914361:CAS:528:DC%2BD1cXhsV2qtrbE10.1002/biot.20080016018956370
– reference: BorisovaGPGenetically engineered mutants of the core antigen of the human hepatitis B virus preserving the ability for native self-assemblyDokl Akad Nauk SSSR1988298147414781:CAS:528:DyaL1cXkt1Sisrg%3D2837379
– reference: BorisovaGRecombinant capsid structures for exposure of protein antigenic epitopesMol Gen. (Life Sci Adv)19876169174
– reference: BirnbaumFNassalMHepatitis B virus nucleocapsid assembly: primary structure requirements in the core proteinJ Virol199064331933301:CAS:528:DyaK3cXkslCnsLs%3D2191149249568
– reference: HattonTZhouSStandringDNRNA- and DNA-binding activities in hepatitis B virus capsid protein: a model for their roles in viral replicationJ Virol199266523252411:CAS:528:DyaK38Xls1Ogtr8%3D1501273289076
– reference: ShlomaiALubelskyYHar-NoyOShaulYThe “Trojan horse” model-delivery of anti-HBV small interfering RNAs by a recombinant HBV vectorBiochem Biophys Res Commun20093906196231:CAS:528:DC%2BD1MXhsVKgtbzJ10.1016/j.bbrc.2009.10.01619818740
– volume: 5
  start-page: e1000563
  year: 2009
  ident: BFsrep11639_CR40
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1000563
– volume: 108
  start-page: 2396
  year: 2011
  ident: BFsrep11639_CR67
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1016404108
– volume: 81
  start-page: 1641
  year: 2007
  ident: BFsrep11639_CR56
  publication-title: J Virol
  doi: 10.1128/JVI.01671-06
– volume: 94
  start-page: 14648
  year: 1997
  ident: BFsrep11639_CR70
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.94.26.14648
– volume: 256
  start-page: 90
  year: 2007
  ident: BFsrep11639_CR63
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2007.06.004
– volume: 327
  start-page: 1094
  year: 2005
  ident: BFsrep11639_CR33
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2004.12.118
– volume: 68
  start-page: 7993
  year: 1994
  ident: BFsrep11639_CR61
  publication-title: J Virol
  doi: 10.1128/jvi.68.12.7993-8000.1994
– volume: 296
  start-page: 677
  year: 1982
  ident: BFsrep11639_CR4
  publication-title: Nature
  doi: 10.1038/296677a0
– volume: 430
  start-page: 20
  year: 2012
  ident: BFsrep11639_CR29
  publication-title: Virology
  doi: 10.1016/j.virol.2012.04.012
– volume: 94
  start-page: 9556
  year: 1997
  ident: BFsrep11639_CR59
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.94.18.9556
– ident: BFsrep11639_CR36
– volume: 1
  start-page: 185
  year: 2009
  ident: BFsrep11639_CR47
  publication-title: Viruses
  doi: 10.3390/v1020185
– volume: 74
  start-page: 11472
  year: 2000
  ident: BFsrep11639_CR57
  publication-title: J Virol
  doi: 10.1128/JVI.74.24.11472-11478.2000
– volume: 288
  start-page: 16949
  year: 2013
  ident: BFsrep11639_CR68
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M112.420521
– volume: 84
  start-page: 7174
  year: 2010
  ident: BFsrep11639_CR35
  publication-title: J Virol
  doi: 10.1128/JVI.00586-10
– volume: 8
  start-page: e75938
  year: 2013
  ident: BFsrep11639_CR60
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0075938
– volume: 77
  start-page: 943
  year: 1994
  ident: BFsrep11639_CR7
  publication-title: Cell
  doi: 10.1016/0092-8674(94)90142-2
– volume: 68
  start-page: 5548
  year: 1994
  ident: BFsrep11639_CR15
  publication-title: J Virol
  doi: 10.1128/jvi.68.9.5548-5555.1994
– ident: BFsrep11639_CR18
  doi: 10.1201/9781420007305.ch9
– volume: 101
  start-page: 2476
  year: 2011
  ident: BFsrep11639_CR26
  publication-title: Biophys J
  doi: 10.1016/j.bpj.2011.10.002
– volume: 5
  start-page: 33
  year: 2005
  ident: BFsrep11639_CR17
  publication-title: BMC Microbiol
  doi: 10.1186/1471-2180-5-33
– volume: 65
  start-page: 6024
  year: 1991
  ident: BFsrep11639_CR41
  publication-title: J Virol
  doi: 10.1128/jvi.65.11.6024-6030.1991
– volume: 75
  start-page: 6367
  year: 2001
  ident: BFsrep11639_CR71
  publication-title: J Virol
  doi: 10.1128/JVI.75.14.6367-6374.2001
– volume: 6
  start-page: e17202
  year: 2011
  ident: BFsrep11639_CR45
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0017202
– volume: 102
  start-page: 15821
  year: 2005
  ident: BFsrep11639_CR58
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0504874102
– volume: 3
  start-page: 771
  year: 1999
  ident: BFsrep11639_CR9
  publication-title: Mol Cell
  doi: 10.1016/S1097-2765(01)80009-5
– volume: 63
  start-page: 4645
  year: 1989
  ident: BFsrep11639_CR28
  publication-title: J Virol
  doi: 10.1128/jvi.63.11.4645-4652.1989
– volume: 66
  start-page: 5232
  year: 1992
  ident: BFsrep11639_CR22
  publication-title: J Virol
  doi: 10.1128/jvi.66.9.5232-5241.1992
– ident: BFsrep11639_CR1
– volume: 162
  start-page: 75
  year: 2010
  ident: BFsrep11639_CR64
  publication-title: Clin Exp Immunol
  doi: 10.1111/j.1365-2249.2010.04226.x
– volume: 102
  start-page: 9020
  year: 2005
  ident: BFsrep11639_CR44
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0502138102
– volume: 74
  start-page: 4721
  year: 2000
  ident: BFsrep11639_CR55
  publication-title: J Virol
  doi: 10.1128/JVI.74.10.4721-4728.2000
– volume: 79
  start-page: 1871
  year: 2005
  ident: BFsrep11639_CR43
  publication-title: J Virol
  doi: 10.1128/JVI.79.3.1871-1887.2005
– volume: 312
  start-page: 993
  year: 1990
  ident: BFsrep11639_CR24
  publication-title: Dokl Akad Nauk SSSR
– volume: 9
  start-page: e102235
  year: 2014
  ident: BFsrep11639_CR52
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0102235
– volume: 330
  start-page: 381
  year: 1987
  ident: BFsrep11639_CR48
  publication-title: Nature
  doi: 10.1038/330381a0
– volume: 54
  start-page: 454
  year: 1973
  ident: BFsrep11639_CR73
  publication-title: Anal Biochem
  doi: 10.1016/0003-2697(73)90374-6
– volume: 298
  start-page: 1474
  year: 1988
  ident: BFsrep11639_CR27
  publication-title: Dokl Akad Nauk SSSR
– volume: 79
  start-page: 1312
  year: 2007
  ident: BFsrep11639_CR65
  publication-title: J Med Virol
  doi: 10.1002/jmv.20939
– volume: 753
  start-page: 51
  year: 2001
  ident: BFsrep11639_CR12
  publication-title: J Chromatogr B Biomed Sci Appl
  doi: 10.1016/S0378-4347(00)00538-7
– volume: 8
  start-page: 1565
  year: 2009
  ident: BFsrep11639_CR19
  publication-title: Expert Rev Vaccines
  doi: 10.1586/erv.09.121
– volume: 481
  start-page: 169
  year: 2000
  ident: BFsrep11639_CR62
  publication-title: FEBS Lett
  doi: 10.1016/S0014-5793(00)01927-X
– volume: 31
  start-page: 4647
  year: 2013
  ident: BFsrep11639_CR66
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2013.07.052
– volume: 423
  start-page: 63
  year: 2012
  ident: BFsrep11639_CR8
  publication-title: J Mol Biol
  doi: 10.1016/j.jmb.2012.06.032
– ident: BFsrep11639_CR38
– volume: 390
  start-page: 619
  year: 2009
  ident: BFsrep11639_CR30
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2009.10.016
– volume: 59
  start-page: 176
  year: 1986
  ident: BFsrep11639_CR11
  publication-title: J Virol
  doi: 10.1128/jvi.59.1.176-180.1986
– volume: 259
  start-page: 342
  year: 1999
  ident: BFsrep11639_CR42
  publication-title: Virology
  doi: 10.1006/viro.1999.9798
– volume: 75
  start-page: 218
  year: 2011
  ident: BFsrep11639_CR13
  publication-title: Protein Expr Purif
  doi: 10.1016/j.pep.2010.09.010
– volume: 64
  start-page: 3319
  year: 1990
  ident: BFsrep11639_CR14
  publication-title: J Virol
  doi: 10.1128/jvi.64.7.3319-3330.1990
– volume: 46
  start-page: 135
  year: 1986
  ident: BFsrep11639_CR10
  publication-title: Gene
  doi: 10.1016/0378-1119(86)90177-0
– volume: 202
  start-page: 912
  year: 1994
  ident: BFsrep11639_CR39
  publication-title: Virology
  doi: 10.1006/viro.1994.1413
– volume: 15
  start-page: 513
  year: 2008
  ident: BFsrep11639_CR54
  publication-title: Chem Biol
  doi: 10.1016/j.chembiol.2008.03.018
– volume: 3
  start-page: 1429
  year: 2008
  ident: BFsrep11639_CR32
  publication-title: Biotechnol J
  doi: 10.1002/biot.200800160
– volume: 172
  start-page: 1777
  year: 2004
  ident: BFsrep11639_CR31
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.3.1777
– volume: 9
  start-page: 65
  year: 2013
  ident: BFsrep11639_CR50
  publication-title: Nanomedicine
  doi: 10.1016/j.nano.2012.05.003
– volume: 42
  start-page: 761
  year: 1982
  ident: BFsrep11639_CR2
  publication-title: J Virol
  doi: 10.1128/jvi.42.3.761-766.1982
– volume: 185
  start-page: 208
  year: 1985
  ident: BFsrep11639_CR75
  publication-title: FEBS Lett
  doi: 10.1016/0014-5793(85)80771-7
– volume: 26
  start-page: 413
  year: 1989
  ident: BFsrep11639_CR23
  publication-title: Mol Immunol
  doi: 10.1016/0161-5890(89)90130-2
– volume: 56
  start-page: 141
  year: 2013
  ident: BFsrep11639_CR20
  publication-title: Intervirology
  doi: 10.1159/000346773
– volume: 84
  start-page: 1607
  year: 2010
  ident: BFsrep11639_CR5
  publication-title: J Virol
  doi: 10.1128/JVI.02033-09
– volume: 9
  start-page: 2415
  year: 2012
  ident: BFsrep11639_CR53
  publication-title: Mol Pharm
  doi: 10.1021/mp200389t
– volume: 66
  start-page: 4107
  year: 1992
  ident: BFsrep11639_CR21
  publication-title: J Virol
  doi: 10.1128/jvi.66.7.4107-4116.1992
– volume: 6
  start-page: 169
  year: 1987
  ident: BFsrep11639_CR49
  publication-title: Mol Gen. (Life Sci Adv)
– ident: BFsrep11639_CR37
– ident: BFsrep11639_CR74
– volume: 83
  start-page: 10616
  year: 2009
  ident: BFsrep11639_CR34
  publication-title: J Virol
  doi: 10.1128/JVI.00749-09
– volume: 86
  start-page: 75
  year: 2005
  ident: BFsrep11639_CR25
  publication-title: J Gen Virol
  doi: 10.1099/vir.0.80580-0
– volume: 89
  start-page: 10046
  year: 1992
  ident: BFsrep11639_CR3
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.89.21.10046
– volume: 9
  start-page: 891
  year: 2011
  ident: BFsrep11639_CR46
  publication-title: Expert Rev Anti Infect Ther
  doi: 10.1586/eri.11.105
– volume: 1
  start-page: 5
  year: 2011
  ident: BFsrep11639_CR51
  publication-title: Sci Rep
  doi: 10.1038/srep00005
– volume: 44
  start-page: 98
  year: 2001
  ident: BFsrep11639_CR6
  publication-title: Intervirology
  doi: 10.1159/000050037
– volume: 21
  start-page: 876
  year: 2002
  ident: BFsrep11639_CR16
  publication-title: EMBO J
  doi: 10.1093/emboj/21.5.876
– volume: 109
  start-page: 5046
  year: 2012
  ident: BFsrep11639_CR69
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1200808109
– volume: 75
  start-page: 6359
  year: 2001
  ident: BFsrep11639_CR72
  publication-title: J Virol
  doi: 10.1128/JVI.75.14.6359-6366.2001
– reference: 2837379 - Dokl Akad Nauk SSSR. 1988;298(6):1474-8
– reference: 15604433 - J Gen Virol. 2005 Jan;86(Pt 1):75-84
– reference: 9405667 - Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14648-53
– reference: 2469950 - Mol Immunol. 1989 Apr;26(4):413-21
– reference: 11413303 - J Virol. 2001 Jul;75(14):6367-74
– reference: 4737496 - Anal Biochem. 1973 Aug;54(2):454-63
– reference: 20427522 - J Virol. 2010 Jul;84(14):7174-84
– reference: 22355524 - Sci Rep. 2011;1:5
– reference: 25014219 - PLoS One. 2014;9(7):e102235
– reference: 22750730 - J Mol Biol. 2012 Oct 12;423(1):63-78
– reference: 21973301 - Expert Rev Anti Infect Ther. 2011 Oct;9(10):891-9
– reference: 10394365 - Mol Cell. 1999 Jun;3(6):771-80
– reference: 3996597 - FEBS Lett. 1985 Jun 3;185(1):208-12
– reference: 19863249 - Expert Rev Vaccines. 2009 Nov;8(11):1565-73
– reference: 1602535 - J Virol. 1992 Jul;66(7):4107-16
– reference: 16247012 - Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15821-6
– reference: 1717713 - J Virol. 1991 Nov;65(11):6024-30
– reference: 23615902 - J Biol Chem. 2013 Jun 7;288(23):16949-59
– reference: 15951426 - Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):9020-5
– reference: 17607782 - J Med Virol. 2007 Sep;79(9):1312-21
– reference: 7966589 - J Virol. 1994 Dec;68(12):7993-8000
– reference: 8004680 - Cell. 1994 Jun 17;77(6):943-50
– reference: 19818740 - Biochem Biophys Res Commun. 2009 Dec 18;390(3):619-23
– reference: 21994545 - Viruses. 2009 Sep;1(2):185-209
– reference: 24086668 - PLoS One. 2013;8(9):e75938
– reference: 2191149 - J Virol. 1990 Jul;64(7):3319-30
– reference: 22775561 - Mol Pharm. 2012 Sep 4;9(9):2415-23
– reference: 18482703 - Chem Biol. 2008 May;15(5):513-9
– reference: 11413302 - J Virol. 2001 Jul;75(14):6359-66
– reference: 17656012 - Cancer Lett. 2007 Oct 18;256(1):90-100
– reference: 2446137 - Nature. 1987 Nov 26-Dec 2;330(6146):381-4
– reference: 3520012 - J Virol. 1986 Jul;59(1):176-80
– reference: 19656897 - J Virol. 2009 Oct;83(20):10616-26
– reference: 9275161 - Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9556-61
– reference: 2226141 - Dokl Akad Nauk SSSR. 1990;312(4):993-6
– reference: 15921513 - BMC Microbiol. 2005;5:33
– reference: 21358805 - PLoS One. 2011;6(2):e17202
– reference: 23933337 - Vaccine. 2013 Sep 23;31(41):4647-54
– reference: 11302448 - J Chromatogr B Biomed Sci Appl. 2001 Mar 25;753(1):51-65
– reference: 17135319 - J Virol. 2007 Feb;81(4):1641-9
– reference: 11867516 - EMBO J. 2002 Mar 1;21(5):876-84
– reference: 7040981 - Nature. 1982 Apr 15;296(5858):677-9
– reference: 11090143 - J Virol. 2000 Dec;74(24):11472-8
– reference: 14734761 - J Immunol. 2004 Feb 1;172(3):1777-85
– reference: 22633898 - Nanomedicine. 2013 Jan;9(1):65-73
– reference: 20735440 - Clin Exp Immunol. 2010 Oct;162(1):75-83
– reference: 22098746 - Biophys J. 2011 Nov 16;101(10):2476-84
– reference: 19714236 - PLoS Pathog. 2009 Aug;5(8):e1000563
– reference: 19939922 - J Virol. 2010 Feb;84(3):1607-15
– reference: 2677399 - J Virol. 1989 Nov;63(11):4645-52
– reference: 15652509 - Biochem Biophys Res Commun. 2005 Feb 25;327(4):1094-9
– reference: 10996318 - FEBS Lett. 2000 Sep 15;481(2):169-76
– reference: 22421137 - Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5046-51
– reference: 8030252 - Virology. 1994 Aug 1;202(2):912-20
– reference: 10388659 - Virology. 1999 Jul 5;259(2):342-8
– reference: 21262835 - Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2396-401
– reference: 6808156 - J Virol. 1982 Jun;42(3):761-6
– reference: 1438193 - Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10046-50
– reference: 15650211 - J Virol. 2005 Feb;79(3):1871-87
– reference: 18956370 - Biotechnol J. 2008 Nov;3(11):1429-36
– reference: 23594863 - Intervirology. 2013;56(3):141-65
– reference: 7520091 - J Virol. 1994 Sep;68(9):5548-55
– reference: 11509871 - Intervirology. 2001;44(2-3):98-114
– reference: 3542716 - Gene. 1986;46(1):135-41
– reference: 1501273 - J Virol. 1992 Sep;66(9):5232-41
– reference: 10775610 - J Virol. 2000 May;74(10):4721-8
– reference: 20854910 - Protein Expr Purif. 2011 Feb;75(2):218-24
– reference: 22595445 - Virology. 2012 Aug 15;430(1):20-9
SSID ssj0000529419
Score 2.3212624
Snippet Hepatitis B virus (HBV) core (HBc) virus-like particles (VLPs) are one of the most powerful protein engineering tools utilised to expose immunological epitopes...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 11639
SubjectTerms 101/28
631/337/475
639/638/92/612/1256
639/925/352/152
82/29
82/83
Alkalies - chemistry
Amino Acid Sequence
Core particles
Deoxyribonucleic acid
DNA
Electrophoresis, Polyacrylamide Gel
Epitopes
Gene therapy
Genetic Therapy - methods
Glutamic acid
Hepatitis
Hepatitis B
Hepatitis B Core Antigens - genetics
Hepatitis B Core Antigens - immunology
Hepatitis B Core Antigens - metabolism
Hepatitis B virus - genetics
Hepatitis B virus - immunology
Hepatitis B virus - metabolism
Humanities and Social Sciences
Hydrogen-Ion Concentration
Hydrolysis
Lysine
Microscopy, Electron
Molecular Sequence Data
multidisciplinary
Mutation
Nucleic acids
Nucleotide sequence
Packaging
Protein engineering
Ribonucleic acid
RNA
Science
Sequence Homology, Amino Acid
Spectrophotometry, Ultraviolet
Vaccines
Vaccines, Virus-Like Particle - immunology
Virion - genetics
Virion - immunology
Virion - metabolism
Virus Assembly - genetics
Virus Assembly - immunology
Virus-like particles
Yeast
Title Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications
URI https://link.springer.com/article/10.1038/srep11639
https://www.ncbi.nlm.nih.gov/pubmed/26113394
https://www.proquest.com/docview/1899482282
https://www.proquest.com/docview/1691598936
https://pubmed.ncbi.nlm.nih.gov/PMC4650659
Volume 5
WOSCitedRecordID wos000356932800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M7P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: 7X7
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: BENPR
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Publicly Available Content Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: PIMPY
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M2P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB71ARIXKI9CaLsyjwOXqE3sxM6poqgVHLqKEEjLKXL8UFdts2Ff0v4O_jBj59Fui7j04ovHyUgz9nz2jL4B-GjwDoA4XIdcKRMynZhQ6oiGOomlLJPYcMV8swk-HIrRKMvbB7dZW1bZnYn-oNYT5d7IDyO8GDCMZiI-rn-HrmuUy662LTQ2YduxJFBfupf3bywui8WirCMUouIQw04dIQTJ1sPQPWx5v0TyTp7Uh5-zZw9VfAeetsCTfG485TlsmOoFPG5aUa5ewp8cdZaNO5ByReTVpXQIlPSV6ERWmjQVp0YTdUP03KyZWGKu6_mKXBhXpD0fz8gJWY6nixlxTJmk7krwCMJkspTKZfT9N9GF8TcNuwG5nVB_BT_PTn98-Rq2DRtCxaiYhwqxFqOldSxipRUqSam2KuGqTHlkJWLRUpUIUERmKaeSxzYTsWSZMSmVLFF0F7aqSWXeAKEqQmjh1vIjZg2TBqGdZFZLzo5oqQL41NmvUC2buWuqcVX4rDoVRW_qAN73onVD4fEvof3OekW7i2fFjekCeNdP4_5zSRVZmckCZdIMESGivjSA143P9H_B22lEacYC4Gve1As4bu_1mWp84Tm-GSLnNEG1PnR-d0utu8q__b_ye_AEYV7iCtzidB-25tOFOYBHaomuMB3AJh9xP4oBbJ-cDvPvA_8ygeN5nA_8lsKZ_Nt5_usvSGYvCw
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL0qUxBseD8CBcxLYhO1iZ3YWSDEq-qo7WgWRSqr4PihjiiZMC8038F_8I1cx0naaRG7LljHcSzn2Pfc-ORcgJcGcwDk4TrkSpmQ6cSEUkc01EksZZHEhitWF5vgg4E4PMyGa_C7_RfGySrbPbHeqPVYuW_kmxEmBgyjmYjfVj9CVzXKna62JTQ8LHbN8iembNM3_Y_4fl_F8fangw87YVNVIFSMilmokBAwWlhndVVYoZKUaqsSroqUR1YiYSpUgVFUZJZyKnlsMxFLlhmTUskSRbHfS7DOEOyiB-vD_v7wS_dVx52bsShrLYyo2MRAV0VIerLVwHeOzZ4XZZ45ma0D3vaN_22qbsL1hlqTd34t3II1U96GK77Y5vIO_BriHEkPeFIsiTz-Jh3HJp3WnshSE6-pNZqoEytrf8_YEvO9mi3JkXEy9NloSt6TxWgynxLnBUqqVmRIMBEgC6mcZqHuExcpPsb7N5DTkoG78PlCZuQe9MpxaR4AoSpC8uTu5VvMGiYNklfJrJacbdFCBfC6xUuuGr92VzbkOK91A1TkHbQCeN41rbxJyd8abbRoyZt9apqfQCWAZ91l3GHcsZEszXiObdIMOS_y2jSA-x6j3VMw_44ozVgAfAW9XQPnXr56pRwd1S7mDHODNMFhvWhxfmpYZwf_8N-DfwpXdw729_K9_mD3EVxDUps4OV-cbkBvNpmbx3BZLRAWkyfNgiXw9aKB_wdxGoab
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL0q5aFueENDC1xeEptomtiJk0WFgDKiKhrNAqTuguPY6qhtJswLzXfwN3wd13GSdlrErgvWcRzLOfY9Nz45F-C1phyAeHjhC6W0z4tI-7IImF9EoZR5FGqheF1sQgwGyeFhOlyD3-2_MFZW2e6J9UZdjJX9Rt4LKDHgFM2SsGcaWcRwr_-u-uHbClL2pLUtp-EgcqCXPyl9m-7u79G7fhOG_U9fP372mwoDvuIsmfmKyAFnubG2V7lJVBSzwqhIqDwWgZFEnnKVU0RNUsMEkyI0aRJKnmodM8kjxajfa3BdWNPyWjY47L7v2BM0HqStmRFLehTyqoDoT7oaAi_x2svyzAtntHXo69_5nyftLtxuCDe-dyvkHqzp8j7cdCU4lw_g15DmS7plgPkS5cmxtMwbOwU-yrJAp7TVBaozg2t3z9igPq1mSzzSVpw-G03xAy5Gk_kUrUMoVq30ECk9wIVUVslQ90lLlx7jXB3wvJDgIXy7khl5BOvluNSbgEwFRKnsvWKHG82lJkoruSmk4DssVx68bbGTqcbF3RYTOclqNQFLsg5mHrzsmlbOuuRvjbZb5GTN7jXNzmDjwYvuMu079jBJlno8pzZxSkyY2G7swWOH1-4plJUHjKXcA7GC5K6B9TRfvVKOjmpvc04ZQxzRsF61mD83rIuDf_LvwT-HW4T27Mv-4GALNojpRlbjF8bbsD6bzPVTuKEWhIrJs3rlIny_atT_AQzhjdo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preparation+by+alkaline+treatment+and+detailed+characterisation+of+empty+hepatitis+B+virus+core+particles+for+vaccine+and+gene+therapy+applications&rft.jtitle=Scientific+reports&rft.au=Strods%2C+Arnis&rft.au=Ose%2C+Velta&rft.au=Bogans%2C+Janis&rft.au=Cielens%2C+Indulis&rft.date=2015-06-26&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=5&rft.issue=1&rft_id=info:doi/10.1038%2Fsrep11639&rft.externalDocID=10_1038_srep11639
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon